Pulmonary arterial hypertension (PAH) is a rare condition that's difficult to treat. The hallmarks of the disease—narrowing ...

Adults with pulmonary arterial hypertension using vs. not using GLP-1 receptor agonists had significantly lower relative ...

Anticoagulant therapy does not extend survival in people with PAH, according to a French study involving the blood thinners.

The addition of sotatercept, an activin-signaling inhibitor, to background therapy results in a lower risk for clinical worsening among adults with pulmonary arterial hypertension (PAH) who were ...

Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) prevalence is higher among Medicaid beneficiaries, with significant racial and ethnic disparities, particularly affecting Black ...

In pulmonary arterial hypertension, GLP-1 receptor agonists significantly lowered the risk of right heart failure compared ...

Sotatercept significantly reduced mortality risk by 85% in patients with PAH compared with placebo. The safety profile of sotatercept remained stable over 2.5 years, with manageable adverse events.

Please provide your email address to receive an email when new articles are posted on . Researchers used data from the GRIPHON study and open-label extension study. The median selexipag dose was 1,000 ...

WINREVAIR significantly reduced the risk of major morbidity and mortality events, the primary endpoint, in adults with PAH (Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality ...